Expiry, cold chain and tender-driven demand make pharmaceutical inventory the most unforgiving there is. DemandIntel right-sizes every reorder on your own data, deterministically, so cash stops dying on the shelf.
In most industries an over-order is a markdown. In pharma and diagnostics it is a total loss: an expired reagent or drug is destroyed, at full cost. Every forecast miss is paid at face value.
Five constraints stack on a single SKU, expiry, cold chain, demand that arrives in tenders, long import lead times, and the duty never to stock out on an installed analyzer. That is why a moving average quietly bleeds cash here.
An over-ordered lot is not discounted; it is destroyed. Pharma inventory charges the full cost of every forecast miss.
Temperature-controlled stock with short shelf life leaves no room for ordering extra to be safe. The buffer has to be exact, not generous.
Volumes arrive in waves: public tenders, regional buying groups, insurance-coverage shifts. Spreadsheet averages break on demand that comes in lumps.
Most reagents and many drugs are imported. The reorder decision is made months before the demand is known, so the forecast has to hold over a long horizon.
You can never fall out of stock on a reagent for an installed instrument. That service constraint forces over-stocking unless the buffer is sized on real error.
Inventory sits at a large share of revenue, and a predictable slice is destroyed at expiry every year. That is cash and margin walking out the door.
of inventory held in pharma in 2025, the single biggest drag on sector cash
written down at one vaccine maker in 2023, cause: shelf-life expiry and inventory in excess of demand
Sources: The Hackett Group, 2026 Working Capital Survey (2025 data); Moderna FY2023 Form 10-K (SEC).
DemandIntel starts with a pre-obsolescence diagnostic: it flags the stock heading for destruction before it gets there, so you can act while it still has value. Then it forecasts intermittent, tender-driven demand reproducibly, rather than smoothing the waves away.
Safety stock is sized on real forecast error and lead-time variability, per SKU, not on a round number, so you protect analyzer uptime without over-buying. Everything installs on-premise: for a health-sector actor, data never leaving your walls is the requirement, not an option.
And because the logic is deterministic and auditable, every number is defensible, to a regulator, to finance, to your own team. It sits beside your ERP and is live in weeks.
No. DemandIntel installs on-premise; nothing leaves your walls. For a health-sector actor, that is the baseline requirement, not a feature.
Yes. It sizes the buffer for service-critical, instrument-locked lines on real demand and lead-time variability, so you protect uptime without over-stocking.
That is exactly where reproducible, intermittent-demand forecasting beats a moving average. It models the waves instead of averaging them away.
That is the first target of the pre-obsolescence diagnostic: the stock heading for destruction, flagged before it gets there.
Picture your next S&OP meeting: one number on screen that nobody argues with. See it free, on your own data, in 45 minutes; and if it does not hold up, we part as friends.